VBIO

Malachite Innovations, Inc. [VBIO] Stock Forecast

Q: What is Malachite Innovations, Inc. stock symbol ?

Malachite Innovations, Inc. is a US stock, located in Los angeles of Ca and trading under the symbol VBIO

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

VBIO Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

VBIO has less than 1 year of cash runway

In the News

11:45 16 Apr 2024 VBIO

Vitality Biopharma Announces Effective S-1 Registration Statement and DTC Eligibility

CLEVELAND, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTC Mkts: VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeutic powers of cannabinoids, today announced that the Securities and Exchange Commission has declared the Company's Form S-1 registration statement effective. The registration statement was filed pursuant to the Securities Purchase Agreement, dated as of August 19, 2021, entered into by the Company with Triton Funds LP (“Triton”) and its affiliate, Triton Funds LLC. The registration statement registers for resale the securities to be issued to Triton under an equity line financing of up to $5,000,000. Only Triton may use the related prospectus to resell the shares registered under the registration statement.

VBIO Financial details

Company Rating

Neutral

Market Cap

Income

-784.27K

Revenue

Book val./share

-0

Cash/share

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

P/E

-22.51

Forward P/E

PEG

2.75

P/S

P/B

22.96

P/C

P/FCF

Quick Ratio

26.44

Current Ratio

26.54

Debt / Equity

LT Debt / Equity

EPS (TTM)

-0.02

EPS next Y

EPS next Q

EPS this Y

-79.86%

EPS next Y

EPS next 5Y

EPS last 5Y

-46.09%

Revenue last 5Y

-100%

Revenue Q/Q

EPS Q/Q

-18.18%

SMA20

-5.26%

SMA50

-5.26%

SMA100

Inst Own

Inst Trans

ROA

-98%

ROE

-82%

ROC

-2.71%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.36015-0.4195

52W High

52W Low

RSI

48.16

Rel Volume

0.01

Avg Volume

98.13K

Volume

1000

Perf Week

-1.39%

Perf Month

-11.25%

Perf Quarter

Perf Half Y

-14.46%

Beta

4.11376

Volatility

0%, 0.01%

Prev Close

4.41%

Price

0.1775

Change

4.41%

VBIO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-03-31

Metric	2017-03-31	2018-03-31	2019-03-31	2020-03-31	2021-03-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.01	0	0	0	0
Net income per share	-0.38	-0.19	-0.61	-0.09	-0.02
Operating cash flow per share	-0.1	-0.12	-0.11	-0.07	-0.03
Free cash flow per share	-0.1	-0.12	-0.11	-0.07	-0.03
Cash per share	0.08	0.03	0.18	0.05	0.02
Book value per share	0.03	0.01	0.15	0.03	0.02
Tangible book value per share	0.03	0.01	0.15	0.03	0.02
Share holders equity per share	0.03	0.01	0.15	0.03	0.02
Interest debt per share	0	0	0	0	0
Market cap	5.3M	9.02M	12.87M	19.83M	19.83M
Enterprise value	4.15M	8.36M	6.89M	17.44M	18.94M
P/E ratio	-1.02	-2.09	-0.64	-4.54	-22.51
Price to sales ratio	32.45	88.04	0	0	0
POCF ratio	-3.83	-3.12	-3.51	-5.52	-12.35
PFCF ratio	-3.83	-3.12	-3.51	-5.52	-12.35
P/B Ratio	14.16	27.98	2.56	15.46	22.96
PTB ratio	14.16	27.98	2.56	15.46	22.96
EV to sales	25.39	81.63	0	0	0
Enterprise value over EBITDA	-0.79	-1.94	-0.34	-3.99	-21.51
EV to operating cash flow	-3	-2.9	-1.88	-4.86	-11.8
EV to free cash flow	-3	-2.9	-1.88	-4.86	-11.8
Earnings yield	-0.98	-0.48	-1.56	-0.22	-0.04
Free cash flow yield	-0.26	-0.32	-0.28	-0.18	-0.08
Debt to equity	0	0	0	0.1	0
Debt to assets	0	0	0	0.05	0
Net debt to EBITDA	0.22	0.15	0.3	0.55	1
Current ratio	1.47	1.91	5.74	1.87	26.54
Interest coverage	-3.44K	0	-673.37	0	0
Income quality	0.27	0.67	0.18	0.82	1.82
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	16.12	24.64	0	0	0
Research and developement to revenue	5.47	18.53	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	4.06	0	0	0
Graham number	0.49	0.24	1.45	0.22	0.08
ROIC	-9.27	-13.64	-0.93	-2.89	-2.71
Return on tangible assets	-4.44	-6.38	-3.31	-1.7	-0.98
Graham Net	0.03	0.01	0.15	0.02	0.02
Working capital	374.37K	322.27K	5M	1.12M	853.89K
Tangible asset value	374.37K	322.27K	5.02M	1.28M	863.39K
Net current asset value	374.37K	322.27K	5M	1.12M	853.89K
Invested capital	0	0	0	0.1	0
Average receivables	24.8K	16.52K	16.6K	9.68K	0
Average payables	0	0	2.6K	433.86K	431.26K
Average inventory	3.24K	0	0	0	0
Days sales outstanding	42.9	49.32	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	8.51	7.4	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-13.94	-13.37	-4.01	-3.4	-1.02
Capex per share	0	0	0	0	0

Quarterly Fundamentals Overview

Last date of statement is 2021-09-30 for Q3

Metric	2020-09-30	2020-12-31	2021-03-31	2021-06-30	2021-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-0.01	0.01	-0.01	-0.01	-0.01
Operating cash flow per share	-0.01	0	-0.01	-0.01	-0.01
Free cash flow per share	-0.01	0	-0.01	-0.01	-0.01
Cash per share	0.03	0.03	0.02	0.01	0
Book value per share	0.01	0.02	0.02	0.01	0
Tangible book value per share	0.01	0.02	0.02	0.01	0
Share holders equity per share	0.01	0.02	0.02	0.01	0
Interest debt per share	0	0	0	0	0
Market cap	19.83M	19.83M	19.83M	19.77M	19.78M
Enterprise value	18.63M	18.41M	18.94M	19.45M	19.72M
P/E ratio	-10.48	7.15	-13.75	-8.07	-9.8
Price to sales ratio	0	0	0	0	0
POCF ratio	-47.72	227.82	-35.58	-35.14	-51.64
PFCF ratio	-47.72	227.82	-35.58	-35.14	-51.64
P/B Ratio	64.7	17.84	22.96	66.42	-225.61
PTB ratio	64.7	17.84	22.96	66.42	-225.61
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-39.39	26.57	-52.53	-31.77	-39.1
EV to operating cash flow	-44.83	211.53	-33.99	-34.57	-51.49
EV to free cash flow	-44.83	211.53	-33.99	-34.57	-51.49
Earnings yield	-0.02	0.03	-0.02	-0.03	-0.03
Free cash flow yield	-0.02	0	-0.03	-0.03	-0.02
Debt to equity	0.5	0.02	0	0	0
Debt to assets	0.11	0.02	0	0	0
Net debt to EBITDA	2.54	-2.05	2.45	0.53	0.11
Current ratio	1.23	3.71	26.54	9.61	0.37
Interest coverage	0	0	0	0	0
Income quality	0.88	0.13	1.55	0.92	0.76
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	0.04	0.08	0.05	0.04	0.02
ROIC	-0.91	-0.4	-0.76	-2.06	5.75
Return on tangible assets	-0.32	0.46	-0.4	-1.85	-7.42
Graham Net	0	0.02	0.02	0.01	0
Working capital	256.88K	1.06M	853.89K	288K	-98.25K
Tangible asset value	306.46K	1.11M	863.39K	297.7K	-87.66K
Net current asset value	214.1K	1.06M	853.89K	288K	-98.25K
Invested capital	0.5	0.02	0	0	0
Average receivables	0	0	0	0	0
Average payables	0	36.04K	36.04K	0	0
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-1.54	0.62	-0.42	-2.06	5.75
Capex per share	0	0	0	0	0

VBIO Frequently Asked Questions

What is Malachite Innovations, Inc. stock symbol ?

Malachite Innovations, Inc. is a US stock , located in Los angeles of Ca and trading under the symbol VBIO

What is Malachite Innovations, Inc. stock quote today ?

Malachite Innovations, Inc. stock price is $0.1775 today.

Is Malachite Innovations, Inc. stock public?

Yes, Malachite Innovations, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Check Those

Similar Market Cap

Company Profile

Volume Average 98.13K
Employee 3
CEO Mr. Michael R. Cavanaugh CPA, J.D.
Headquarters Los Angeles,CA,US
IPO Date 2022-01-31
Website http://www.malachiteinnovations.com

Vitality Biopharma, Inc. engages in the development of cannabinoid pharmaceuticals for the treatment of inflammatory disorders in the United States. The company is developing tetrahydrocannabinol glycoside (VBX-100), an oral cannabinoid prodrug for inflammatory bowel disease and irritable bowel syndromes. The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016. Vitality Biopharma, Inc. was founded in 2007 and is headquartered in Los Angeles, California.